Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -14.07% | -11.81% | -8.89% | 2.57% | 19.02% |
| Total Other Revenue | 17.75% | 2.78% | -9.55% | -25.56% | -36.47% |
| Total Revenue | -8.97% | -9.38% | -9.00% | -3.47% | 4.39% |
| Cost of Revenue | -15.49% | -11.35% | -6.12% | 10.30% | 33.77% |
| Gross Profit | -4.26% | -8.09% | -10.72% | -10.95% | -9.88% |
| SG&A Expenses | 5.53% | -1.00% | -6.34% | -5.36% | -2.75% |
| Depreciation & Amortization | -23.00% | -14.23% | -4.13% | 1.21% | 8.53% |
| Other Operating Expenses | -6.64% | 4.83% | 19.86% | 35.16% | 58.37% |
| Total Operating Expenses | -4.93% | -3.46% | -1.09% | 5.57% | 15.06% |
| Operating Income | 0.91% | -2.99% | -8.40% | -16.47% | -28.06% |
| Income Before Tax | 1.76% | -14.82% | -38.02% | -44.10% | -54.19% |
| Income Tax Expenses | -- | 97.03% | 94.36% | 24.56% | -359.74% |
| Earnings from Continuing Operations | 0.44% | -16.66% | -40.72% | -45.00% | -52.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.44% | -16.66% | -40.72% | -45.00% | -52.83% |
| EBIT | 0.91% | -2.99% | -8.40% | -16.47% | -28.06% |
| EBITDA | 2.36% | -2.75% | -9.59% | -17.69% | -29.31% |
| EPS Basic | 21.77% | 5.58% | -15.25% | -24.96% | -38.97% |
| Normalized Basic EPS | 21.23% | 15.98% | 9.73% | -3.44% | -20.45% |
| EPS Diluted | 21.77% | 5.58% | -15.25% | -24.96% | -38.97% |
| Normalized Diluted EPS | 21.23% | 15.98% | 9.73% | -3.44% | -20.45% |
| Average Basic Shares Outstanding | 30.42% | 26.54% | 22.29% | 16.13% | 9.95% |
| Average Diluted Shares Outstanding | 30.42% | 26.54% | 22.29% | 16.13% | 9.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
